Pancreatic Cancer Research

ResearcherMarche Polytechnic UniversityActive in the last 2 years

Alessandro Bittoni

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4056-0067; OpenAlex author ID A5036243769. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
60
Papers, trials and grants by year

2014: 1 paper · 2015: 6 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 18

  1. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  2. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv). Co-author DOI 10.1038/s41416-022-02086-w↗
  3. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomi… Co-author DOI 10.1016/j.ejca.2021.02.023↗
  4. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter surve… Co-author DOI 10.1016/j.esmoop.2021.100238↗
  5. Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer. Co-author DOI 10.21037/atm-20-3499↗
  6. Retrospective Cohort Study of Caveolin-1 Expression as Prognostic Factor in Unresectable Locally Advanced or Metastatic Pancreatic Cancer Patients. Co-author DOI 10.3390/curroncol28050303↗
  7. Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by th… Co-author DOI 10.3390/cancers12061681↗
  8. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival. Co-author DOI 10.3389/fonc.2019.00874↗
  9. Yes-associated protein and immunosuppressive microenvironment in pancreatic cancer development: a new strategy to improve immunotherapy efficacy? First author DOI 10.21037/jtd.2017.06.60↗
  10. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2015.11.016↗
  11. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? First author DOI 10.1016/j.ejso.2016.06.398↗
  12. [Treatment of pancreatic cancer. Actuality and perspective]. Co-author DOI 10.1701/1868.20404↗
  13. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Co-author DOI 10.18632/oncotarget.4492↗
  14. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Co-author DOI 10.18632/oncotarget.5197↗
  15. Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. Co-author DOI 10.2217/fon.15.27↗
  16. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon.15.98↗
  17. HER family receptor expression and prognosis in pancreatic cancer. Co-author DOI 10.5301/jbm.5000157↗
  18. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Co-author DOI 10.1155/2014/183852↗

Closest collaborators

The 25 strongest of 60 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefano Cascinu · 13 shared papers, 2014–2025 · strength 0.89
  2. Michele Reni · 7 shared papers, 2015–2025 · strength 0.62
  3. Rossana Berardi · 6 shared papers, 2015–2021 · strength 0.59
  4. Elisa Giommoni · 4 shared papers, 2020–2025 · strength 0.47
  5. Michèle Milella · 4 shared papers, 2020–2025 · strength 0.47
  6. Andrea Spallanzani · 4 shared papers, 2021–2025 · strength 0.47
  7. Mario Scartozzi · 4 shared papers, 2015–2025 · strength 0.41
  8. Stefania Mosconi · 4 shared papers, 2015–2025 · strength 0.39
  9. Enrico Vasile · 3 shared papers, 2020–2025 · strength 0.38
  10. Marina Macchini · 3 shared papers, 2021–2025 · strength 0.37
  11. Maria Grazia Rodriquenz · 3 shared papers, 2021–2025 · strength 0.37
  12. Mariacristina Di Marco · 3 shared papers, 2021–2025 · strength 0.37
  13. Silvia Bozzarelli · 3 shared papers, 2021–2025 · strength 0.37
  14. Giulia Orsi · 3 shared papers, 2021–2025 · strength 0.37
  15. Ingrid Garajová · 3 shared papers, 2021–2025 · strength 0.37
  16. Guido Giordano · 3 shared papers, 2021–2025 · strength 0.37
  17. Ilario Giovanni Rapposelli · 3 shared papers, 2021–2025 · strength 0.37
  18. Monica Niger · 3 shared papers, 2021–2025 · strength 0.37
  19. Giampaolo Tortora · 3 shared papers, 2021–2025 · strength 0.37
  20. Kalliopi Andrikou · 7 shared papers, 2014–2016 · strength 0.33
  21. Letizia Procaccio · 2 shared papers, 2023–2025 · strength 0.28
  22. Sara Lonardi · 2 shared papers, 2023–2025 · strength 0.28
  23. Lisa Salvatore · 2 shared papers, 2023–2025 · strength 0.28
  24. Aldo Scarpa Scarpa · 3 shared papers, 2015–2025 · strength 0.25
  25. Francesco Piva · 4 shared papers, 2015–2019 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.